Gene Logic has entered into a drug repositioning and development agreement with Eli Lilly and Co. to seek alternative development paths for multiple Lilly drug candidates that were discontinued or de-prioritized in clinical trials for reasons other than safety. The agreement provides for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lilly’s contribution as the originator of the compound. Gene Logic will the option to...